Results 41 to 50 of about 8,927 (183)

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

Phytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee, Yu Jin So, Il‐Joo Jo, Ji Yong Jang, Tae Han Yook, Jun Ho Lee, Sung Wook Kim, Kangwook Lee, Soo Jung Park, Gabsik Yang   +9 more
wiley   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab

JEADV Clinical Practice, 2023
Secukinumab is a monoclonal antibody used to specifically inhibit pathologic interleukin‐17 and therefore effectively manage conditions like plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Although we know that antitumor necrosis factor
Daniela Anghel, Mihaela Georgescu, Marcela Poenaru, Diana Maria Orleanu, George Sorin Tiplica   +4 more
doaj   +1 more source

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease

The Journal of Dermatology, EarlyView.
ABSTRACT Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating ...
Luis Puig, Tsen‐Fang Tsai, Enrique R. Soriano, Tina Bhutani, Megan Miller, Alexa P. Kollmeier, Shu Li, Hewei Li, Sarah Ofori, Jeffrey Pawlikowski, Elizabeth Adamson, Melinda Gooderham, Angela Londoño Garcia, Mark Lebwohl, Peter Nash   +14 more
wiley   +1 more source

Effect of Anti‐IL‐23 and Anti‐IL‐17 Therapy on Darier Disease: A Case Series

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Darier disease is a rare ATP2A2‐related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real‐world case series of eight patients, anti‐IL‐17 therapy showed a more consistent early signal of clinical benefit than anti‐IL‐23 therapy, with greater
Maione Vincenzo, Zanghi Silvia, Catapano Cecilia, Bighetti Stefano, Cattaneo Isacco, Venturini Marina, Bettolini Luca   +6 more
wiley   +1 more source

A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab

Drugs - Real World Outcomes, 2019
Purpose This real-world study evaluated the feasibility of assessing patient-reported symptom improvement and treatment satisfaction using a web-based survey among patients with ankylosing spondylitis (AS) treated with secukinumab.
Marina Magrey, Michael Bozyczko, Daniel Wolin, Margaret Mordin, Lori McLeod, Eric Davenport, Costel Chirila, Yujin Park   +7 more
doaj   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies

Rheumatology and Therapy
Introduction The aim of this work is to evaluate secukinumab vs. placebo in a challenging-to-treat and smaller US patient subpopulation of the international FUTURE 2–5 studies in patients with psoriatic arthritis (PsA).
Alan J. Kivitz, Joel M. Kremer, Clarence W. Legerton, Luminita Pricop, Atul Singhal   +4 more
doaj   +1 more source

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

Dermatology and Therapy, 2018
Introduction Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate to severe plaque psoriasis. Here, we report 16-week results from CLARITY, a second
Jerry Bagel, John Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi, Andrew Blauvelt, Mark Lebwohl   +11 more
doaj   +1 more source

Divergent Paths: A Comprehensive Review of Mechanisms and Clinical Implications in Atopic Dermatitis and Psoriasis

Allergy, EarlyView.
ABSTRACT Atopic dermatitis and psoriasis are two common cutaneous chronic inflammatory diseases. Although they share similar immunological mechanisms, their clinical implications in the patient are different. This review compares both diseases from different points of view such as genetics, natural history, triggers of disease, and skin barrier defects
Tali Czarnowicki, Kazunari Sugita, Zenas Yiu, Sandra Díez‐Ribas, Irene Garcia‐Jimenez, Emma Guttman‐Yassky, Luis F. Santamaria‐Babí   +6 more
wiley   +1 more source